Medifast Future Growth
Future criteria checks 0/6
Medifast's revenue and earnings are forecast to decline at 18.8% and 63.2% per annum respectively. EPS is expected to decline by 63.5% per annum. Return on equity is forecast to be 16.5% in 3 years.
Key information
-63.2%
Earnings growth rate
-63.5%
EPS growth rate
Personal Products earnings growth | 0% |
Revenue growth rate | -18.8% |
Future return on equity | 16.5% |
Analyst coverage | Low |
Last updated | 27 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 756 | 34 | 50 | 63 | 2 |
12/31/2024 | 694 | 21 | 39 | 42 | 2 |
12/31/2023 | 1,072 | 99 | 141 | 148 | N/A |
9/30/2023 | 1,218 | 120 | 174 | 189 | N/A |
6/30/2023 | 1,373 | 133 | 200 | 214 | N/A |
3/31/2023 | 1,530 | 142 | 199 | 215 | N/A |
12/31/2022 | 1,599 | 144 | 178 | 195 | N/A |
9/30/2022 | 1,639 | 151 | 116 | 135 | N/A |
6/30/2022 | 1,662 | 157 | 68 | 96 | N/A |
3/31/2022 | 1,603 | 165 | 40 | 73 | N/A |
12/31/2021 | 1,526 | 164 | 60 | 95 | N/A |
9/30/2021 | 1,413 | 158 | 97 | 122 | N/A |
6/30/2021 | 1,271 | 150 | 130 | 147 | N/A |
3/31/2021 | 1,097 | 125 | 174 | 184 | N/A |
12/31/2020 | 935 | 103 | 139 | 145 | N/A |
9/30/2020 | 841 | 95 | 140 | 145 | N/A |
6/30/2020 | 759 | 76 | 118 | 121 | N/A |
3/31/2020 | 726 | 76 | 72 | 78 | N/A |
12/31/2019 | 714 | 78 | 74 | 84 | N/A |
9/30/2019 | 689 | 74 | 70 | 80 | N/A |
6/30/2019 | 638 | 72 | 60 | 69 | N/A |
3/31/2019 | 568 | 64 | 67 | 76 | N/A |
12/31/2018 | 501 | 56 | 56 | 61 | N/A |
9/30/2018 | 433 | 47 | 51 | 55 | N/A |
6/30/2018 | 371 | 40 | 57 | 61 | N/A |
3/31/2018 | 330 | 34 | 51 | 55 | N/A |
12/31/2017 | 302 | 28 | 40 | 43 | N/A |
9/30/2017 | 286 | 25 | N/A | 33 | N/A |
6/30/2017 | 277 | 24 | N/A | 27 | N/A |
3/31/2017 | 273 | 20 | N/A | 24 | N/A |
12/31/2016 | 275 | 18 | N/A | 25 | N/A |
9/30/2016 | 273 | 18 | N/A | 28 | N/A |
6/30/2016 | 271 | 17 | N/A | 30 | N/A |
3/31/2016 | 272 | 19 | N/A | 27 | N/A |
12/31/2015 | 273 | 20 | N/A | 29 | N/A |
9/30/2015 | 274 | 18 | N/A | 28 | N/A |
6/30/2015 | 277 | 18 | N/A | 27 | N/A |
3/31/2015 | 279 | 19 | N/A | 25 | N/A |
12/31/2014 | 285 | 21 | N/A | 26 | N/A |
9/30/2014 | 267 | 27 | N/A | 33 | N/A |
6/30/2014 | 285 | 27 | N/A | 31 | N/A |
3/31/2014 | 307 | 28 | N/A | 38 | N/A |
12/31/2013 | 324 | 27 | N/A | 42 | N/A |
9/30/2013 | 363 | 21 | N/A | 35 | N/A |
6/30/2013 | 367 | 22 | N/A | 37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MED *'s earnings are forecast to decline over the next 3 years (-63.2% per year).
Earnings vs Market: MED *'s earnings are forecast to decline over the next 3 years (-63.2% per year).
High Growth Earnings: MED *'s earnings are forecast to decline over the next 3 years.
Revenue vs Market: MED *'s revenue is expected to decline over the next 3 years (-18.8% per year).
High Growth Revenue: MED *'s revenue is forecast to decline over the next 3 years (-18.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MED *'s Return on Equity is forecast to be low in 3 years time (16.5%).